logo
Plus   Neg
Share
Email

Gemphire Therapeutics Inc. (GEMP) Is Up Sharply On Study Results

Gemphire Therapeutics Inc. (GEMP) announced after the bell Thursday that its Phase 2b trial of gemcabene met its primary endpoint.

Gemphire Therapeutics gapped open sharply higher Friday morning and is now up 5.08 at $10.32 on the highest volume of the year. The stock has jumped to a 5-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT